EUCTR2016-003426-16-HU进行中（未招募）1 期
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
CB Biopharma SPR0 个研究点目标入组 435 人开始时间: 2018年2月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 435
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Must be at least 18 years of age
- •- Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit
- •- Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator’s Global Assessment (IGA) score >=3 on a 5-point scale
- •- Subject is a candidate for systemic PSO therapy
- •- Female subject of child bearing potential must be willing to use highly effective method ofcontraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 320
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •- Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections
- •- Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
- •- Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
- •- Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
- •- Presence of active suicidal ideation or severe depression
- •- Subject has concurrent or a recent history (<5 years) of malignancy
研究者
相似试验
进行中（未招募）
1 期
A study with a initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasisModerate to severe chronic plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2016-003426-16-DECB Biopharma SPR400
进行中（未招募）
1 期
Multicenter, double-blind, placebo-controlled, Randomized phase III study with an open phase extension of amifampridine phosphate (3,4-Diaminopyridine Phosphate) in patients with Lambert-Eaton myasthenic syndrome (LEMS)ambert-Eaton Myasthenic Syndrome (LEMS)MedDRA version: 14.1Level: LLTClassification code 10067685Term: Lambert-Eaton myasthenic syndromeSystem Organ Class: 100000004852EUCTR2010-021850-20-DECatalyst Pharmaceutical Partners, Inc.79
进行中（未招募）
不适用
Multicenter, double-blind, placebo-controlled, Randomized phase III study with an open phase extension of amifampridine phosphate (3,4-Diaminopyridine Phosphate) in patients with Lambert-Eaton myasthenic syndrome (LEMS)EUCTR2010-021850-20-BGCatalyst Pharmaceutical Partners, Inc.79
进行中（未招募）
1 期
Multicenter, double-blind, placebo-controlled, Randomized phase III study with an open phase extension of amifampridine phosphate (3,4-Diaminopyridine Phosphate) in patients with Lambert-Eaton myasthenic syndrome (LEMS)ambert-Eaton Myasthenic Syndrome (LEMS)MedDRA version: 14.1Level: LLTClassification code 10067685Term: Lambert-Eaton myasthenic syndromeSystem Organ Class: 100000004852EUCTR2010-021850-20-HUCatalyst Pharmaceutical Partners, Inc.79
进行中（未招募）
1 期
Multicenter, double-blind, placebo-controlled, Randomized phase III study with an open phase extension of amifampridine phosphate (3,4-Diaminopyridine Phosphate) in patients with Lambert-Eaton myasthenic syndrome (LEMS)ambert-Eaton Myasthenic Syndrome (LEMS)MedDRA version: 14.1Level: LLTClassification code 10067685Term: Lambert-Eaton myasthenic syndromeSystem Organ Class: 100000004852EUCTR2010-021850-20-CZCatalyst Pharmaceutical Partners, Inc.79